Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 5/20 | 0.36 |
| ▸ | RARA | P10276 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014009 | 1.00 | RXRB (0.41) | RXRBRXRARARBRARARARG | |
| SCHEMBL29385555 | 1.00 | RXRB (0.41) | RXRBRXRARARBRARARARG | |
| SCHEMBL12274098 | 1.00 | RXRB (0.41) | RXRBRXRARARBRARARARG | |
| SCHEMBL362701 | 1.00 | RXRB (0.41) | RXRBRXRARARBRARARARG | |
| Hydrochloric Acid SCHEMBL1566413 | 0.99 | RXRB (0.40) | RXRBRXRARARBRARARARG | |
| SCHEMBL22135784 | 0.95 | RXRB (0.39) | RXRBRXRARARBRARARARG | |
| SCHEMBL2009917 | 0.93 | RXRB (0.38) | RXRBRXRARARBRARARARG | |
| SCHEMBL2015664 | 0.93 | RXRB (0.47) | RXRBRXRARARBRARARARG | |
| SCHEMBL2013786 | 0.93 | RXRB (0.40) | RXRBRXRARARBRARARARG | |
| SCHEMBL15271560 | 0.92 | CA1 (0.34) | RXRBRXRACA1CA2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977902-A | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazole-3-yl ] -2-methylbenzoic acid | 湖南九维生物医药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-113195459-B | Process for racemization of (5R) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H isoxazol-3-yl ] -2-methyl-benzoic acid | 英特维特国际股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-113242854-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-119977902-A | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazole-3-yl ] -2-methylbenzoic acid | 湖南九维生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977902-A | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazole-3-yl ] -2-methylbenzoic acid | 湖南九维生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977902-A | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazole-3-yl ] -2-methylbenzoic acid | 湖南九维生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-113195459-B | Process for racemization of (5R) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H isoxazol-3-yl ] -2-methyl-benzoic acid | 英特维特国际股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-113242854-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113242854-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113242854-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113227060-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-113227060-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-113227060-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-11530187-B2 | Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid | INTERVET INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220073479-A1 | Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid | INTERVET INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530187-B2 | Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid | GABRA5, KDM5A, COX5A | RXRB 1488/4885RXRA 706/4885RARB 1347/4885 |
| US-20220073479-A1 | Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid | KDM5A, GABRA5, KDM5B | RXRB 1393/4885RXRA 659/4885RARB 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.